NRGene Technologies: What really remains for shareholders from the Above Food deal
The Above Food deal created revenue, cash, shares, and future royalty rights for NRGene, but not everything that came in through the transaction stays with shareholders. The gap between what was booked, what is still deferred, and what must flow back to Above Food is the real issue.
The main article argued that NRGene's 2025 should be read through commercialization, not software. This follow-up isolates the one transaction that moved the report more than anything else: Above Food.
That matters because this is not a one-line deal. It shows up at the same time in revenue, marketable securities, deferred revenue, a liability that has to be paid back to the counterparty, and future royalty rights. Anyone looking only at the revenue line or only at the cash balance misses the one question that matters here: how much of that value actually remains with shareholders after all the intermediate layers are stripped out.
This is therefore an all-in cash-capture question, not a profit question. The right test is what has already become clean cash, what is still conditional, and what remains only as future upside.
The headline is simple, the structure is not
The original agreement was signed on August 28, 2023 and had three main components: C$2.5 million in cash, C$10 million in Above Food shares at the IPO price, and royalty rights tied to future commercialization. In pea and hemp, NRGene is entitled to 10% of gross sales. In the disease-resistant canola project and the high-protein canola project, it is entitled to 80% of gross sales.
On top of that, Above Food received two options to buy itself out of the royalty stream: a first option for C$20 million over 36 months from deal completion, and a second option for C$40 million over the following 36 months. That clause matters, but it needs to be read correctly. It is not current consideration. It is the counterparty's right to choose, later, whether to pay to eliminate the royalty burden.
The transaction was amended during 2024 and 2025. The key changes were an 8% interest charge for delayed payment and the issuance of additional shares to compensate for share-price volatility. That is where the economics become much less clean: this is no longer just an asset sale, but a structure in which Above Food's share price, the timing of sales, and the final true-up all affect what really stays inside NRGene.
| Component | What the deal says | What it means for shareholders |
|---|---|---|
| Immediate cash consideration | C$2.5 million in cash | Real cash, but only part of it arrived directly in cash |
| Share consideration | C$10 million in Above Food shares | Value depends on the share price and the timing of monetization |
| Future royalties | 10% in pea and hemp, 80% in the two canola projects | Real recurring upside, but not current cash |
| Buyout options | C$20 million and C$40 million | Above Food's option, not NRGene's guaranteed cash |
| 2024 and 2025 amendments | 8% interest and extra shares | More upside potential, but also more complexity and more post-sale reconciliation |
What came in is not the same as what stays
As of March 25, 2026, the deal note already shows a much more detailed picture than the headline. For the cash leg, NRGene received $632 thousand in cash and another 1.45 million shares. By that date, sales of those shares had generated $1.533 million in cash, while the company still held roughly 710 thousand Above Food shares worth $1.16 million.
For the share leg, originally set at C$10 million, the company received 1.437 million Above Food shares, including an extra 300 thousand shares as compensation. Sales of that block had already generated about $2.5 million in cash.
But this is the clause that determines what actually remains. Under the latest amendment, if selling the shares received against the cash leg, including interest, generates cash above the amount owed, 80% of that excess has to be paid back to Above Food. In other words, not all of the upside from share sales belongs to NRGene. As of December 31, 2025 the company had already recorded a $1.069 million liability for excess consideration, plus about $267 thousand of deferred revenue for the portion that remains with it.
The March 27, 2026 presentation made that mechanism even clearer. Management said excess consideration had reached $1.4 million, of which 80% would go back to Above Food and only 20% would stay with NRGene. In plain terms, what can look from the outside like a $1.4 million bonus shrinks to roughly $0.28 million that remains in the group before any further accounting treatment. That also lines up with the roughly $0.3 million of deferred revenue recorded for NRGene's 20% share.
That is the key shareholder takeaway: the stream of Above Food share monetization created liquidity, but it also created a giveback mechanism. The right number to focus on is the net retention, not the gross cash inflow.
The most important asset has still not left the company
The most interesting part of the deal is also the part that is still unfinished. Ownership of the patent applications and the license in the fungal-disease-resistant canola project is meant to transfer to Above Food only after all the shares received in the deal are sold. Until then, the group continues to hold the IP as well as the commercialization and royalty rights for that project.
That is exactly why the company recorded $1.98 million of deferred revenue for that project in 2025. NRGene's revenue-recognition policy explicitly says deferred revenue represents collections from customers when the service or the license has not yet been provided. So this is not fictional value, but it is also not fully released shareholder cash. In accounting terms, the company is saying something very clear: value has come in, but the underlying performance obligation has not yet been completed.
The balance sheet shows the same point from two directions. First, year-end 2025 includes $388 thousand of intangible assets held for sale. Second, the deferred-revenue line stands at $2.396 million, and the company explicitly identifies within it $1.98 million for the canola project and roughly $267 thousand for NRGene's 20% share of the excess consideration. The deal is spread across several lines, which is exactly why a superficial read of any single line does not work.
That is the heart of the accounting gap. In 2025 the group recognized $2.168 million of revenue from the Above Food deal, but at the same time it kept part of the economics outside clean shareholder cash through deferred revenue, a liability to return excess consideration, and an unfinished transfer of a key canola asset.
Even the positive 2025 cash flow does not settle the argument
It is fair to say that the cash position looked much better by the end of 2025. Operating cash flow turned positive at $855 thousand, and investing cash flow included $970 thousand of proceeds from the sale of intangible assets. That is a major improvement over 2024.
But anyone trying to understand what really remains for shareholders from Above Food cannot stop there. The same cash-flow statement also shows a $1.828 million increase in deferred revenue and a $1.361 million increase in accrued expenses and other liabilities. So the jump in operating cash flow does not reflect only clean cash locked inside the company. It also reflects the build-up of balance-sheet items that keep part of the consideration in a deferred or encumbered state.
That is why the right question is not whether the deal created value. It clearly did. The real question is how that value is split across four different layers:
| Layer | What is there now | How much is already accessible to shareholders |
|---|---|---|
| Cash and share-sale proceeds already received | About $4.5 million according to the March 2026 presentation | Partly accessible, but not all of the excess stays with NRGene |
| Remaining Above Food shares | About 710 thousand shares worth $1.16 million at December 31, 2025, and only about 57 thousand shares left according to the presentation | Becomes cash only after monetization, at the actual market price |
| Deferred revenue | $1.98 million for the canola project and about $267 thousand for NRGene's share of the excess consideration | Not free cash, but value waiting for completion or accounting release |
| Future rights | 80% of future payments in the two canola projects and 10% in pea and hemp | Real upside, but not current cash |
So the answer to "what remains for shareholders" is not one number. Three things remain: cash that has already come in, a far smaller slice of the excess consideration than a first read suggests, and meaningful future rights in the canola economics. What does not remain clean is most of the upside created by share monetization, because that must be sent back to Above Food.
Conclusion
The Above Food deal did two things at once. It improved NRGene's liquidity, but it also made the link between revenue, cash, and shareholder value much less direct. That is not a technical footnote. It is the core of how the deal should be read.
By late March 2026, it is already clear that this was not just an accounting entry. The deal generated real cash, improved liquidity, and left NRGene with royalty rights that could still become meaningful. But it is just as clear that not everything that looks like consideration remains inside the group. Eighty percent of the excess consideration is not NRGene's, and the most important canola asset is still sitting in between the cash proceeds and full economic release.
So the right conclusion is neither that Above Food was a weak deal nor that it solved commercialization. The better conclusion is narrower: the transaction created value, but a large part of that value is still moving through a narrow pipe of share sales, deferred revenue, and counterparty true-ups. Anyone trying to understand what remains for shareholders should now spend less time on the 2025 revenue headline and more time on three concrete checkpoints: the sale of the remaining shares, the final settlement of the excess-consideration mechanism, and the company's ability to turn the retained canola rights into recurring income or royalties rather than a one-off accounting bridge.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.